EMEA News
Most Popular EMEA Story
New death reports prompt EMA review of Gilenya
European regulators are taking a closer look at Novartis' ($NVS) multiple sclerosis pill Gilenya. After the November death of a 59-year-old patient who'd just begun Gilenya therapy, triggering an FDA Read more...
Latest Headlines
- January 20, 2012
- December 23, 2011
- September 12, 2011
- June 24, 2011
- June 10, 2011
- March 18, 2011
- March 2, 2011
- October 22, 2010
- May 27, 2010
- May 21, 2010
- November 23, 2009
- November 20, 2009
- October 1, 2009
- July 24, 2009
- December 19, 2008
- November 20, 2008
- November 13, 2008
- October 27, 2008
- October 24, 2008
- October 23, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
